Empowering Client-Facing Teams for Product Launch Excellence

Introduction

A leading biopharmaceutical company’s oncology division approached PDG in the Spring of 2024 with a complex challenge. Managing a portfolio of several products across two specialized teams, they were preparing to launch a new product in a novel therapeutic area while simultaneously dealing with disruptive protocol changes to an existing treatment. Their sales teams, though experienced in their established therapeutic areas, needed to rapidly develop new expertise while maintaining momentum with their existing products. Based on PDG’s proven track record with other divisions of the company, they engaged PDG to design and implement a comprehensive solution that would address these multifaceted challenges.

Challenge

The company faced unique challenges across its two specialized teams, each requiring tailored approaches to overcome specific obstacles while maintaining portfolio performance:

The Solid Tumor Team (75 representatives, including six first-line leaders) confronted dual challenges that required both forward-looking preparation and enhancement of existing capabilities:

• New Product Launch Preparation: The team needed to quickly develop clinical expertise in a new therapeutic area while preparing for a product launch scheduled for late 2024
• Legacy Product Enhancement: They needed to integrate new data sets for their established product with 10+ years in the portfolio to support continued growth and maintain a strong market position

The Specialty Treatment Team (30 representatives, including two first-line leaders) faced immediate disruptions to their existing sales model that threatened current performance:

• Protocol Change Impact: A change in treatment protocol introduced treatment with another therapy before their product could be used, significantly disrupting their sales cycle.
• Portfolio Management: The team needed to increase focus on one legacy product with 10+ years in the portfolio to drive utilization and earlier diagnosis, helping offset the impact of the protocol change.

What began as a solution for one team demonstrated such value that a second team actively sought inclusion mid-year, showcasing the program’s effectiveness in addressing complex sales challenges.

Solution

PDG was engaged by the Solid Tumor team, but after the solution’s measurable impact and effectiveness became known, the Specialty Treatment team actively sought to participate mid-year. This organic expansion demonstrated the program’s value and resulted in a comprehensive solution that supported both teams’ unique needs.

The multi-faceted program included:

Digital Platform Implementation

At the core of the solution was leveraging an AI-driven platform, which transformed how sales representatives acquired and retained critical knowledge:

The solution featured bite-sized knowledge modules (2-5 minutes) optimized for mobile use between customer visits, allowing seamless integration into daily workflows. Confidence-based assessments dynamically adjusted to each rep’s demonstrated knowledge level, while diverse content formats (videos, podcasts, infographics, PDFs) accommodated different learning styles, making complex information more accessible and engaging.

Strategic Content Development

Understanding that effective learning requires relevant, targeted content, PDG developed team-specific materials that addressed the unique challenges each group faced:

For the Solid Tumor Team, this included comprehensive launch readiness materials for the new therapeutic area, focused modules on new data for their legacy product, and strategies for maintaining existing product performance during the launch period. These resources equipped representatives to balance portfolio priorities while developing new expertise.

For the Specialty Treatment Team, PDG developed content addressing protocol changes to help sales teams navigate the new landscape effectively. They created materials supporting earlier diagnosis initiatives and comprehensive modules for portfolio selling approaches, enabling representatives to maximize customer interactions across multiple products.

The comprehensive program expanded beyond traditional product knowledge to include advanced clinical knowledge building, HCP engagement strategies, portfolio selling approaches, change management, and customer collaboration techniques, creating a holistic approach to sales enablement.

Comprehensive Program Management

Beyond content development, PDG implemented a robust program management framework that ensured sustainable engagement and continuous improvement, featuring a “push” system that delivered targeted content directly to representatives’ devices. PDG also generated regular analytics for leadership decision-making, provided ongoing platform support and strategic guidance, and facilitated cross-team knowledge-sharing through collaborative learning initiatives. This comprehensive approach ensured sustainable engagement and continuous improvement aligned with company goals.

Leadership Integration and Alignment

PDG ensured leadership alignment by providing performance analytics with coaching guidance, enabling leaders to identify team strengths and improvement areas. This approach embedded new practices into management routines and fostered a culture of continuous development.

96% of sales representatives actively engaged with the platform, resulting in a 10% knowledge lift and exceeding sales targets despite market disruptions.

Results

The partnership between PDG and our biopharmaceutical client delivered meaningful business impact across multiple dimensions. The comprehensive approach to knowledge and skill building directly translated to improved commercial performance and exceptional user engagement. Results included:

Future Use

Building on this success, PDG continues to partner with the client in 2025 to reinforce clinical expertise, optimize sales enablement, and support future product launches. The comprehensive program has established a foundation for continued commercial excellence across their oncology portfolio, combining innovative digital reinforcement tools with strategic sales enablement approaches.